After years of disappointing ALS clinical trial results, this year's Sheila Essey Award recipient for significant contributions in ALS research is shifting to prevention.
Researchers demonstrated the model's excellent performance, raising hopes that it can someday prove a valuable tool for reducing such events in hospitalized patients.
Clinical trial holds delay therapies getting to market and may be on the rise in oncology. But there's a lot the public doesn't know about how often these holds happen and why.
AXS-05, a combination of dextromethorphan and bupropion, led to a rapid and sustained improvement in agitation related to Alzheimer's disease in the phase 3 ACCORD trial.